Timothy Miller

Ten leaders in the field of ALS research put their heads together on Oct. 24, 2009

posted on October 30, 2009 - 5:18pm
  An all-day "think tank" to consider priorities for amyotrophic lateral sclerosis (ALS) research based on the latest information was conducted with ten of the leading scientists and clinicians in the field and senior MDA staff in Tucson, Ariz., on Saturday, Oct. 24, 2009. Each specialist introduced his or her area of expertise and led an approximately 20-minute discussion, gathering input...

The first ALS trial to block abnormal SOD1 protein using ‘antisense’ is set to open by the end of 2009

posted on October 19, 2009 - 9:00pm
A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

Can toxic genes be blocked to treat disease?

posted on January 1, 2007 - 3:02pm
QUEST Vol. 14, No. 1
Since the 1990s, gene therapy - the insertion of functional genes to compensate for nonfunctional ones - has been the goal of researchers working in several muscular dystrophies, spinal muscular atrophy, Friedreich's ataxia, metabolic muscle diseases and myotubular myopathy.